... ENG

ESMO 2024 - Complete program listing (14 programs)

Created by oncoXchange | September 27th 2024

Read Now

Dr. Tarantino - DESTINY BREAST

Q1: In which patient profiles would you consider standard of care T-DXd for in the 2L HER2+ mBC setting? And is there a patient profile you would not consider it?

Unlocking Insights: Your Questions Answered by Dr. Paolo Tarantino on 2L HER2+ Breast Cancer and the DESTINY BREAST Trial

Watch Now

ASCO 2024 - Current State of Adjuvant Therapy Strategies: Consider Subtype, Nodal Involvement, Residual Risk

Created by oncoXchange | June 17th 2024

Read Now

Dr. Tarantino - DESTINY BREAST

Q2: What are the steps you take to optimally manage ILD for patients on T-DXd (The 5 S Rules)?

Unlocking Insights: Your Questions Answered by Dr. Paolo Tarantino on 2L HER2+ Breast Cancer and the DESTINY BREAST Trial

Watch Now

ASCO 2024 - Abemaciclib After Progression on Prior CDK4/6 Inhibition Improved PFS in HR+/HER2- Advanced Breast Cancer

Created by oncoXchange | June 10th 2024

Read Now

ASCO 2024 - Complete program listing (16 programs)

Created by oncoXchange | June 2nd 2024

Read Now

SABCS 2024 - Complete program listing (32 programs)

Created by oncoXchange | December 11th 2024

Read Now

All editorial programs